Revitalist Receives Approval from Biomedical Research Alliance of New York Permitting the Company to Perform Human Subjects Clinical Trials

Rhea-AI Summary

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) has received independent institutional review board (IRB) approval from the Biomedical Research Alliance of New York (BRANY). This approval allows Revitalist to conduct clinical trials across its nine clinics and develop proprietary data in the psychedelic field. The company employs trained professionals from the U.S. Department of Health and Human Services, enhancing its credibility. CEO Kathryn Walker emphasized that this partnership showcases Revitalist's leadership in healthcare innovation.

Positive

• IRB approval from BRANY enhances credibility and allows clinical trials at all nine Revitalist clinics.
• Revitalist employs trained professionals, ensuring high standards in human research protection.
• Partnership with BRANY supports data publication and research in translational medicine.

Negative

• None.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) is pleased to announce its research division has received independent institutional review board approval (“IRB”) from the highly renowned Biomedical Research Alliance of New York (“BRANY”). IRB approval from BRANY will facilitate clinical trials at all nine Revitalist clinics, development of proprietary data, and partnerships advancing the field of psychedelics.

Each Revitalist location has trained professionals from the U.S. Department of Health and Human Services who have completed Human Research Protection Training. This specialized training is a prerequisite to IRB approval and distinguishes Revitalist from other companies in the psychedelic space.

BRANY has been serving academic medical centers, research organizations, and research sites for over 20 years. The organization reflects the highest standards in human research protection while providing ongoing communication that promotes stakeholder engagement.

Revitalist CEO, Kathryn Walker states, “Partnering with BRANY allows Revitalist the ability to show our thought leadership in this rapidly evolving sector of healthcare. Publishing data and research in our speciality of translational medicine will highlight the evolution of best practices on national and international levels.”

ABOUT REVITALIST LIFESTYLE AND WELLNESS LTD.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) is a publicly traded company, headquartered in Knoxville, Tennessee, with clinics operating across the United States and expanding. Revitalist is dedicated to empowering individuals toward an improved quality of well-being through a combination of comprehensive care and future-centric treatments provided by medical professionals, mental health experts, and chronic pain specialists. The company proudly practices translational medicine which is supported by three main pillars: bench side, bedside, and community, with a goal to improve the global healthcare system significantly. Since opening their first clinic in 2018, Revitalist has provided thousands of infusions for patients suffering from treatment-resistant conditions. Additionally, Revitalist offers a number of lifestyle optimization services and vitamin infusions that can bring anyone closer to total wellness. For additional information and to be added to the Company’s mailing list, please click here.

Twitter: @RevitalistCorp
Facebook: @RevitalistLifestyleandWellnessLtd.
Instagram: @RevitalistCorp
LinkedIn: @RevitalistLifestyleAndWellnessLtd

On Behalf of the Board
Kathryn Walker
Chief Executive Officer

Forward Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of Revitalist to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.

Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005451/en/

For further information please contact:

Revitalist Lifestyle and Wellness Ltd.

Email: IR@revitalist.com

Tel: (865) 585-8414

Source: REVITALIST LIFESTYLE AND WELLNESS LTD.

FAQ

What does the IRB approval mean for Revitalist (RVLWF)?

The IRB approval allows Revitalist to conduct clinical trials at its clinics, enhancing research capabilities and credibility.

How many clinics does Revitalist operate?

Revitalist operates nine clinics across the United States.

Who approved Revitalist's clinical trials?

The Biomedical Research Alliance of New York (BRANY) approved Revitalist's clinical trials.

What is the significance of the partnership with BRANY?

The partnership with BRANY allows Revitalist to publish data and advance research in the field of psychedelics.

Who is the CEO of Revitalist?

The CEO of Revitalist is Kathryn Walker.